Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for DarioHealth Corp are anything but routine. A single 10-K can weave together FDA pathways, digital therapeutics algorithms, and multi-year clinical data—details essential to gauging how its chronic-condition platform turns R&D into recurring revenue. If you’ve ever opened a filing looking for patent amortization or payer adoption metrics, you know the frustration. Stock Titan solves that pain.
Our AI breaks down DarioHealth Corp annual report 10-K simplified, highlights segment revenue from employer contracts, and flags capitalized software costs in minutes. The same engine delivers bullet-proof context for each DarioHealth Corp quarterly earnings report 10-Q filing and pushes alerts for every DarioHealth Corp 8-K material events explained. Need to track DarioHealth Corp insider trading Form 4 transactions? We stream DarioHealth Corp Form 4 insider transactions real-time, mapping each executive move to option grant dates and clinical milestones. Questions like “How is share-based compensation trending?” or “Did management sell stock before a material announcement?” are answered instantly.
Whether you’re understanding DarioHealth Corp SEC documents with AI for diligence or performing a DarioHealth Corp earnings report filing analysis, the platform connects forms to real-world drivers:
- DarioHealth Corp executive stock transactions Form 4 reveal insider confidence as new condition modules launch.
- DarioHealth Corp proxy statement executive compensation links pay structures to clinical outcome targets.
- 10-Qs trace membership growth across diabetes, hypertension, and behavioral health programs.
Skip the 300-page PDFs. Stock Titan delivers concise, expert narratives, real-time updates, and the clarity investors need to act.
Dare Bioscience, Inc. (DARE) filed a Form 4 disclosing the grant of 4,500 non-qualified stock options to independent director Jessica D. Grossman on 07/09/2025. The options carry an exercise price of $2.44 per share and expire on 07/09/2035.
Vesting terms: The award vests in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company’s first annual shareholder meeting following the grant. Full acceleration occurs upon a change in control, provided the director remains on the board.
Post-grant holdings: Following this transaction, Dr. Grossman beneficially owns 4,500 derivative securities (stock options) and no change was reported for common shares in Table I, indicating the grant is additive rather than a sale.
Governance context: Routine equity compensation for directors aligns incentives with shareholder interests but results in a modest potential dilution of approximately 0.01% of outstanding shares, assuming ~45 million shares outstanding (company total not provided in filing). No cash was exchanged and there is no immediate earnings impact.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
What is the core business of DarioHealth Corp?
How does DarioHealth differentiate its digital health solutions?
Who can benefit from DarioHealth’s platform?
What role does data analytics play in DarioHealth’s solutions?
How does DarioHealth integrate behavioral health into its offerings?
What are the key strategic advantages of DarioHealth’s platform?
